Kim L. L. Habets

Kim L. L. Habets

Auto-generated profile, based on publicly available information

Kim L. L. Habets

LUMC, Leiden, Netherlands

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JSJolien Suurmond
Jolien Suurmond
KHKim L. L. Habets
Kim L. L. Habets
ADAnnemarie L. Dorjée
Annemarie L. Dorjée
THTom W. Huizinga
Tom W. Huizinga
RTRené E. M. Toes
René E. M. Toes
Mast cells (MC) are most well known for their role in innate immune responses. However, MC are increasingly recognized as important regulators of adaptive immune responses, especially in setting the outcome of T cell responses. In this study we determined the effect of MC on cytokine production by naive and memory human Th cells. CD4+ T cells were cultured with MC supernatant or control medium, after which cytokine production by T cells was determined. Supernatant of activated MC specifically increased the number of IL-17–producing T cells. This enhancement of Th17 cell number was specifically observed for the memory CD4+ T cell population and not for the naive CD4+ T cell population. The effect of MC was inhibited for ∼80% by blocking Abs to IL-1β and the rIL-1R antagonist anakinra. Importantly, secretion of active IL-1β by MC was independent of caspase activity, indicating that Th17 cell expansion by MC occurred through inflammasome-independent IL-1β. Together, these studies reveal a role for human MC in setting the outcome of T cell responses through release of caspase-independent IL-1β, and provide evidence for a novel contribution of MC in boosting the Th17 axis in mucosal immune responses.

5 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IMIlliana Meurs
Illiana Meurs
LCLaura Calpe-Berdiel
Laura Calpe-Berdiel
KHKim L. L. Habets
Kim L. L. Habets
YZYing Zhao
Ying Zhao
SKSuzanne J. A. Korporaal
Suzanne J. A. Korporaal
MEMiranda Van Eck
Miranda Van Eck
ABCA7, a close relative of ABCA1 which facilitates cholesterol efflux to lipid-poor apoproteins, has been implicated in macrophage lipid efflux and clearance of apoptotic cells in in vitro studies. In the current study, we investigated the in vivo effects of macrophage ABCA7 deficiency on lipid metabolism and atherosclerosis. Chimeras with dysfunctional ABCA7 in macrophages and other blood cells were generated by transplantation of bone marrow from ABCA7 knockout (KO) mice into irradiated low-density lipoprotein receptor (LDLr) KO mice. Unexpectedly, macrophage ABCA7 deficiency did not significantly affect atherosclerosis susceptibility of LDLr KO mice after 10 weeks Western-type diet feeding. However, ABCA7 deficiency was associated with 2-fold (p0.05) as compared to wild type transplanted mice. However, single deletion of ABCA1 had a similar effect (1.8-fold, p<0.05). Macrophage foam cell accumulation in the peritoneal cavity was reduced in ABCA1/ABCA7 dKO transplanted animals as compared to single ABCA1 KO transplanted mice, which was associated with increased ABCG1 expression. Interestingly, spleens of ABCA1/ABCA7 double KO transplanted mice were significantly larger as compared to the other 3 groups and showed massive macrophage lipid accumulation, a reduction in CD3+ T-cells, and increased expression of key regulators of erythropoiesis. In conclusion, deletion of ABCA7 in bone marrow-derived cells does not affect atherogenesis in the arterial wall neither in the absence or presence of ABCA1. Interestingly, combined deletion of bone marrow ABCA1 and ABCA7 causes severe splenomegaly associated with cellular lipid accumulation, a reduction in splenic CD3+ T cells, and induced markers of erythropoeisis. Our data indicate that ABCA7 may play a role in T cell proliferation and erythropoeisis in spleen.

1 June 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
TMT Messemaker
T Messemaker
JSJ Suurmond
J Suurmond
KHK Habets
K Habets
MHM Heijink
M Heijink
JSJ Schonkeren
J Schonkeren
FKF Kurreeman
F Kurreeman
Background Mast cell numbers are increased in the rheumatoid arthritis joint. We have previously shown that mast cells can be activated by IgG-ACPA leading to the production of proinflammatory cytokines. However, not much is known about the resulting function when mast cells would repeatedly engage IgG, a likely scenario given the long life span of mast cells (up to a year) and the perpetual presence of IgG-ACPA in the joints. We have recently shown that mast cells triggered repeatedly through their Ig Fc epsilon receptor undergo a reprogramming of their responses (Suurmond et al. JACI, 2016 by expressing de-novo transcribed genes in the antigen presentation and pathogen defence response pathways. Objectives The aim of the current work was to determine whether mast cells show similar changes in their response mode following repeated interactions with IgG. Methods Human cord blood-derived mast cells were treated for 2 weeks with plate-bound IgG. The expression profile of naive or treated mast cells was measured through RNA sequencing, quantitative RT-PCR, flow cytometry. Protein secretion was measured with ELISA and Luminex assays. Metabolic changes were measured using HPLC mass-spectrometry. Results Similar to our previous work on Fc Epsilon receptor, we observe a dampening of the normal IgG responses with a set of novel genes upregulated. Interestingly, de-novo expressed genes consisted of DHCR7 and DHCR24, key enzymes in the cholesterol pathway. Pathway analysis confirms an enrichment of genes in this pathway following repeated IgG triggering. Preliminary data on metabolic profiling reveals a decrease in phospholipid levels in repeatedly activated mast cells. Conclusions Our study provides evidence that mast cells are reprogrammed upon repeated IgG triggering. In contrast to repeated Fc Epsilon Receptor triggering, different pathways are affected, implying stimulus-specific effects. Our work has important implications for the understanding the role of mast cells in rheumatoid arthritis. Disclosure of Interest None declared

1 June 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
FRFelice Rivellese
Felice Rivellese
JSJ. Suurmond
J. Suurmond
KHK. Habets
K. Habets
ADA.L. Dorjée
A.L. Dorjée
APAmato de Paulis
Amato de Paulis
RTR.E. Toes
R.E. Toes
Background Mast cells have been implicated in the pathogenesis of Rheumatoid Arthritis (RA). In particular, activation of mast cells by IL-33 has been linked to the development of arthritis in animal models. Likewise, increased levels of IL-33 have been described in the sera and synovial fluid of RA patients. However, little is known about the influence of IL-33-triggered human mast cells on immune responses in RA. Objectives To evaluate the activation of mast cells by IL-33 and immune complexes and their ability to modulate monocyte-mediated immune responses in the context of Anti-Citrullinated Protein Antibody-positive (ACPA+) RA. Methods Human mast cells were stimulated with IL-33 combined with immune complexes (IC) formed by plate bound total IgG or IgG-ACPA bound to citrullinated fibrinogen. Mast cell activation was analysed by measuring cytokine production with ELISA and a multiplex assay. By immunofluorescence, the cellular interactions of mast cells were assessed in the synovial tissue of patients with established ACPA+ RA undergoing knee joint replacement. Finally, the influence of mast cells on LPS-induced monocyte activation was evaluated by measuring cytokine production by ELISA and membrane markers by flow cytometry. Results IL-33 enhanced the activation of mast cells by IC, including IgG-ACPA IC, as demonstrated by a significant increase of IL-8 production. Further analysis of mast cell supernatants showed a differential activation of mast cells, with IC preferentially inducing pro-inflammatory mediators (e.g. IL-8) and IL-33 inducing significantly higher amounts of potential immunomodulatory mediators (e.g. IL-10 and histamine). Additionally, the combined stimulation with IL-33 and IgG IC showed a significant synergistic effect exclusively for the IL-33-induced immunomodulatory mediators. Ex vivo, in the synovial membrane of RA patients, mast cells were frequently found in contact with CD14+ cells. Finally, mast cells activated with IL-33 and IC inhibited, mainly via the release of IL-10 and histamine, the LPS-induced production of the prototypical pro-inflammatory cytokine TNF-α and the upregulation of the co-stimulatory molecule CD80 by monocytes. Conclusions We here show that human mast cells acquire an immunomodulatory phenotype when exposed to IL-33, releasing regulatory mediators even when triggered with pro-inflammatory stimuli such as immune complexes. This finding was corroborated by the evidence of mast cell-monocyte interactions at synovial level and by the functional demonstration that mast cells triggered with IL-33 and IC are able to suppress monocyte pro-inflammatory activation. Overall, our study suggests a novel immunomodulatory role for human mast cells that might have a functional relevance in the pathogenesis of RA. References Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nature reviews Immunology. 2008;8(6):478-86. Brown MA, Hatfield JK. Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy? Front Immunol. 2012;3:147. Liew FY. IL-33: a Janus cytokine. Ann Rheum Dis. 2012;71 Suppl 2:i101-4. Acknowledgements This research was conducted while F. Rivellese was an ARTICULUM Fellow. Disclosure of Interest None declared

1 March 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
TMTobias Messemaker
Tobias Messemaker
JSJolien Suurmond
Jolien Suurmond
KHKim L Habets
Kim L Habets
MHMarieke Heijink
Marieke Heijink
JSJoris J Schonkeren
Joris J Schonkeren
FKFina Kurreeman
Fina Kurreeman
Background Traditionally, immunological responses have been studied in-vitro whereby immune cells are subject to certain stimuli following which alterations in RNA and/or protein expression are measured. Recently, we have challenged this model by showing that mast cells (cells specialised in allergic reactions) triggered repeatedly through their Ig Fc epsilon receptor undergo a reprogramming of their responses (Suurmond et al. JACI, 2016). The differential expression of genes upon a single trigger were dampened and de-novo transcribed genes were observed. The latter belonged to the antigen presentation and pathogen defence response pathways implying a dramatic change in the cellular response mode. We have now extended this work by challenging mast cells with plate-bound IgG in a repeated mode, a model relevant for arthritic diseases where mast cells and IgG immune complexes are likely to interact. Materials and methods Human cord blood-derived mast cells were treated for 2 weeks with plate-bound IgG. The expression profile of naive or treated mast cells was measured through RNA sequencing, quantitative RT-PCR, flow cytometry. Protein secretion was measured with ELISA and Luminex assays. Metabolic changes were measured using HPLC mass-spectrometry. Results Similar to our previous work on Fc Epsilon receptor, we observe a dampening of the normal IgG responses with a set of novel genes upregulated. Interestingly, de-novo expressed genes consisted of DHCR7 and DHCR24, key enzymes in the cholesterol pathway. Pathway analysis confirms an enrichment of genes in this pathway following repeated IgG triggering. Preliminary data on metabolic profiling reveals a decrease in phospholipid levels in repeatedly activated mast cells. Conclusions Our study provides evidence that mast cells are also reprogrammed upon repeated IgG triggering. In contrast to repeated Fc Epsilon Receptor triggering, different pathways are affected, implying stimulus-specific effects. Our work has important implications for revisiting the traditional immunological models in the (in-vitro) modelling of chronic (arthritic) diseases.